Recent Updates
Recently added Catalysts
ELDN Positive Sentiment

Xenotransplantation at the brink of breakthrough: A new era in organ transplantation

Key Takeaway: The article discusses the promising advancements in xenotransplantation, highlighting its potential to revolutionize organ transplantation. It emphasizes the transformative impact on patients' lives and the innovative mechanisms behind this approach. The focus on clinical trials and patient stories underscores the significance of these developments in the field.
Price reaction · baseline $2.6 (2025-08-14 close) · hit after-hours · clean, no other ELDN news in the window
day 0 close
+1.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Potential breakthrough in organ transplantation.
  • Focus on patient stories highlights transformative impact.
  • Innovative approach through xenotransplantation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+90%
120-day peak, hindsight
Typical move
6.5%
average across 7 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
AT-1501
Phase 2 · Kidney Transplant Rejection

Full Press Release Details

Transforming Lives. One Organ at a Time.
• Overview Focus Patient Stories Clinical Trials In The News
• Science Mechanism of Action Pipeline Publications & Presentations In The News
• Team Overview Leadership Board of Directors
• Investors Overview News & Events Press Releases Events Publications & Presentations Corporate Governance Governance Overview Committee Composition Ethics Hotline Financials SEC Filings Stock Information Stock Quote & Chart Analyst Coverage Resources Investor FAQs Email Alerts Contact IR
• Culture/Careers Culture Careers
• Contact
• Focus
• Patient Stories
• Clinical Trials
• In The News
• Mechanism of Action
• Pipeline
• Publications & Presentations
• In The News
• Overview
• Leadership
• Board of Directors
• Overview
• News & Events Press Releases Events Publications & Presentations
• Corporate Governance Governance Overview Committee Composition Ethics Hotline
• Financials SEC Filings
• Stock Information Stock Quote & Chart Analyst Coverage
• Resources Investor FAQs Email Alerts Contact IR
• Press Releases
• Events
• Publications & Presentations
• Governance Overview
• Committee Composition
• Ethics Hotline
• SEC Filings
• Stock Quote & Chart
• Analyst Coverage
• Investor FAQs
• Email Alerts
• Contact IR
• Culture
• Careers
• Privacy Overview
• Necessary
• Analytics
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.

Frequently Asked Questions

What is xenotransplantation?

Xenotransplantation involves transplanting organs from one species to another, aiming to address organ shortages.

How does xenotransplantation benefit patients?

It offers a potential solution to the shortage of human organs, significantly improving patient outcomes.

What are the key advancements in this field?

Recent innovations focus on enhancing compatibility and reducing rejection rates in transplant recipients.

What role do clinical trials play in xenotransplantation?

Clinical trials are crucial for testing the safety and efficacy of xenotransplantation techniques.

Last updated: Aug 14, 2025